ERAGNY-SUR-OISE, France--(BUSINESS WIRE)--Regulatory News:
SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments, today announces that on November 30, 2016 it has suspended the liquidity contract entrusted to Invest Securities on February 5, 2015.
At November 30, 2016, the following assets were allocated to the liquidity contract:
• 45,382 Safe Orthopaedics’ shares and
• 28,908.62 euros in cash.
From December 1, 2016 and until the renewal of the authorisation to be put to the vote by shareholders in the Combined General Meeting of January 25, 2017, Kurma Biofunds, a major shareholder and director of Safe Orthopaedics, has arranged for Invest Securities to implement a liquidity contract in accordance with the code of conduct established by AMAFI and approved by a decision of the Autorité des Marchés Financiers on March 21, 2011.
The following assets have been allocated to the liquidity agreement:
• 25,000 Safe Orthopaedics’ shares and
• 20,000 euros in cash
About Safe Orthopaedics
Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine™ Kits are CE-marked and FDA cleared. The company is based at Eragny-sur-Oise (France), and has 34 employees.
For more information, visit: www.SafeOrtho.com